BR112017015123A2 - derivados de indol como inibidores da replicação viral do dengue - Google Patents

derivados de indol como inibidores da replicação viral do dengue

Info

Publication number
BR112017015123A2
BR112017015123A2 BR112017015123A BR112017015123A BR112017015123A2 BR 112017015123 A2 BR112017015123 A2 BR 112017015123A2 BR 112017015123 A BR112017015123 A BR 112017015123A BR 112017015123 A BR112017015123 A BR 112017015123A BR 112017015123 A2 BR112017015123 A2 BR 112017015123A2
Authority
BR
Brazil
Prior art keywords
dengue viral
compounds
viral replication
indole derivatives
relates
Prior art date
Application number
BR112017015123A
Other languages
English (en)
Other versions
BR112017015123B1 (pt
Inventor
Didier M Marchand Arnaud
Rudolf Romanie Kesteleyn Bart
Alice Marie-Eve Bardiot Dorothee
Bonfanti Jean-François
Jean-Marie Bernard Raboisson Pierre
Hugo Maria Jonckers Tim
Original Assignee
Janssen Pharmaceuticals Inc
Katholieke Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Katholieke Univ filed Critical Janssen Pharmaceuticals Inc
Publication of BR112017015123A2 publication Critical patent/BR112017015123A2/pt
Publication of BR112017015123B1 publication Critical patent/BR112017015123B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção se relaciona com compostos de indol mono- ou dissubstituídos, métodos para prevenir ou tratar infecções virais do dengue por uso dos referidos compostos e se relaciona também com os referidos compostos para uso como um medicamento, mais preferencialmente para uso como um medicamento para tratar ou prevenir infecções virais do dengue. a presente invenção se relaciona além do mais com composições farmacêuticas ou preparações de combinação dos compostos, com as composições ou preparações para uso como um medicamento, mais preferencialmente para a prevenção ou tratamento de infecções virais do dengue. a invenção se relaciona também com processos para preparação dos compostos.
BR112017015123-5A 2015-01-16 2016-01-15 Derivados de indol como inibidores da replicação viral do dengue BR112017015123B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15151481.7 2015-01-16
EP15151481 2015-01-16
PCT/EP2016/050715 WO2016113371A1 (en) 2015-01-16 2016-01-15 Indole derivatives as dengue viral replication inhibitors

Publications (2)

Publication Number Publication Date
BR112017015123A2 true BR112017015123A2 (pt) 2018-03-13
BR112017015123B1 BR112017015123B1 (pt) 2022-11-16

Family

ID=52345130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015123-5A BR112017015123B1 (pt) 2015-01-16 2016-01-15 Derivados de indol como inibidores da replicação viral do dengue

Country Status (30)

Country Link
US (1) US10029984B2 (pt)
EP (1) EP3244886B1 (pt)
JP (1) JP6830438B2 (pt)
KR (1) KR102509848B1 (pt)
CN (1) CN107428685B (pt)
AR (1) AR103412A1 (pt)
AU (1) AU2016208015B2 (pt)
BR (1) BR112017015123B1 (pt)
CA (1) CA2972329C (pt)
CL (1) CL2017001822A1 (pt)
DK (1) DK3244886T3 (pt)
EA (1) EA032362B1 (pt)
ES (1) ES2904575T3 (pt)
HK (2) HK1246688A1 (pt)
HR (1) HRP20211782T1 (pt)
HU (1) HUE057299T2 (pt)
IL (1) IL253434B (pt)
JO (1) JOP20150335B1 (pt)
LT (1) LT3244886T (pt)
MA (1) MA41341A (pt)
MX (1) MX2017009309A (pt)
MY (1) MY187068A (pt)
PH (1) PH12017501272A1 (pt)
SG (1) SG11201705760XA (pt)
SI (1) SI3244886T1 (pt)
TW (1) TWI700274B (pt)
UA (1) UA123002C2 (pt)
UY (1) UY36518A (pt)
WO (1) WO2016113371A1 (pt)
ZA (1) ZA201704783B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20180495A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Deribados de indol sustituidos como inhibidores de replicación viral del dengue
BR112018069601A2 (pt) 2016-03-31 2019-01-29 Janssen Pharmaceuticals Inc derivados de indolina substituídos como inibidores da replicação viral da dengue
MA44502A (fr) 2016-04-01 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) * 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
IL270727B2 (en) 2017-05-22 2023-03-01 Janssen Pharmaceuticals Inc Transduced indulin derivatives as inhibitors of dengue virus replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2326631A4 (en) * 2008-08-18 2012-03-21 Univ Yale MODULATORS OF MIF
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors

Also Published As

Publication number Publication date
SI3244886T1 (sl) 2022-02-28
ZA201704783B (en) 2019-01-30
TW201632502A (zh) 2016-09-16
KR20170103820A (ko) 2017-09-13
MX2017009309A (es) 2018-02-09
IL253434B (en) 2020-09-30
CL2017001822A1 (es) 2018-03-16
ES2904575T3 (es) 2022-04-05
MA41341A (fr) 2017-11-21
TWI700274B (zh) 2020-08-01
DK3244886T3 (da) 2022-01-17
AU2016208015A1 (en) 2017-07-06
WO2016113371A1 (en) 2016-07-21
CA2972329C (en) 2023-03-28
US20180002282A1 (en) 2018-01-04
EP3244886A1 (en) 2017-11-22
MY187068A (en) 2021-08-28
HK1247611A1 (zh) 2018-09-28
CN107428685B (zh) 2021-06-15
HUE057299T2 (hu) 2022-05-28
BR112017015123B1 (pt) 2022-11-16
JP2018503642A (ja) 2018-02-08
US10029984B2 (en) 2018-07-24
LT3244886T (lt) 2021-12-27
AU2016208015B2 (en) 2020-05-07
UA123002C2 (uk) 2021-02-03
EA201791614A1 (ru) 2017-11-30
HRP20211782T1 (hr) 2022-03-04
JP6830438B2 (ja) 2021-02-17
CA2972329A1 (en) 2016-07-21
SG11201705760XA (en) 2017-08-30
IL253434A0 (en) 2017-09-28
JOP20150335B1 (ar) 2022-03-14
KR102509848B1 (ko) 2023-03-13
PH12017501272A1 (en) 2018-01-15
HK1246688A1 (zh) 2018-09-14
EA032362B1 (ru) 2019-05-31
AR103412A1 (es) 2017-05-10
EP3244886B1 (en) 2021-10-27
CN107428685A (zh) 2017-12-01
UY36518A (es) 2016-07-29

Similar Documents

Publication Publication Date Title
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112018068956A2 (pt) derivados do composto indol substituídos como inibidores da replicação viral da dengue
BR112018068676A2 (pt) derivados de indol substituídos como inibidores da replicação viral do dengue
BR112017006708A2 (pt) indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018068640A2 (pt) derivados de indolina substituídos como inibidores da replicação viral do dengue
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2016, OBSERVADAS AS CONDICOES LEGAIS